Oseltamivir phosphate for suspension is bioequivalent to TAMIFLU in healthy volunteers: a randomized, open-label clinical study

• Main Authors: Ying Wang (Author), Bangzhong Tang (Author), Jing Xie (Author), Xiaoqin Wang (Author), Peng Ren (Author), Guangmei Wu (Author), Cuixia He (Author), Minhui Zhu (Author), Yue Su (Author), Jiaxiang Ding (Author), Yuanyuan Xu (Author), Ling Fan (Author), Qin Ge (Author), Yuzhou Ding (Author), Juan Zhu (Author), Bingyan Liu (Author), Rongfang Shan (Author), Huan Zhou (Author)
• Format: Book
• Published: BMC, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Purpose The study was aimed at evaluating the bioequivalence and safety of oseltamivir phosphate for suspension, provided by Shenzhen Beimei Pharmaceutical Co. Ltd. and manufactured by Hetero Labs Limited, and the reference product TAMIFLU® in healthy Chinese subjects. Methods A single-dose...